Sagimet Biosciences Inc. Earnings Per Share (Basic)
Sagimet Biosciences Inc. (SGMT) reported Earnings Per Share (Basic) of -$0.26 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- Sagimet Biosciences Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.26.
- Sagimet Biosciences Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.33.
- Sagimet Biosciences Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.29.
- Sagimet Biosciences Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.40.
- Sagimet Biosciences Inc. earnings per share, basic for fiscal 2025 was -$1.58.
- Sagimet Biosciences Inc. earnings per share, basic for fiscal 2024 was -$1.45.
- Sagimet Biosciences Inc. earnings per share, basic for fiscal 2023 was -$2.66.
- Sagimet Biosciences Inc. earnings per share, basic for fiscal 2022 was -$165.20.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.26 10-Q · filed 2026-08-11 | -$0.57 10-Q · filed 2026-08-11 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.33 10-Q · filed 2026-05-12 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.02 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$0.69 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$1.01 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.58 10-K · filed 2026-03-11 |
| 2025-09-30 | -$0.40 10-Q · filed 2025-11-13 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.28 10-Q · filed 2025-11-13 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.32 10-Q · filed 2026-08-11 | -$0.89 10-Q · filed 2026-08-11 | -$1.39 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.56 10-Q · filed 2026-05-12 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.78 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2024-12-31 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$0.96 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$1.45 10-K · filed 2026-03-11 |
| 2024-09-30 | -$0.45 10-Q · filed 2025-11-13 | -$0.71 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.95 10-Q · filed 2025-11-13 | -$1.29 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-06-30 | -$0.25 10-Q · filed 2025-08-13 | -$0.48 10-Q · filed 2025-08-13 | -$0.81 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.14 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-03-31 | -$0.23 10-Q · filed 2025-05-08 | -$0.56 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.90 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.58 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2023-12-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2025-03-12 | -$0.70 derived: net income ÷ weighted average shares · filed 2025-03-12 | -$1.53 derived: net income ÷ weighted average shares · filed 2025-03-12 | -$2.66 10-K · filed 2025-03-12 |
| 2023-09-30 | -$0.35 10-Q · filed 2024-11-14 | -$1.43 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$3.22 10-Q · filed 2024-11-14 | -$5.74 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2023-06-30 | -$35.80 10-Q · filed 2024-08-14 | -$71.39 10-Q · filed 2024-08-14 | -$110.40 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$150.73 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2023-03-31 | -$35.58 10-Q · filed 2024-05-15 | -$74.63 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$114.98 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$153.35 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2022-12-31 | -$39.06 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$79.41 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$117.78 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$165.20 10-K · filed 2024-03-25 |
| 2022-09-30 | -$40.34 10-Q · filed 2023-11-13 | -$78.72 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$126.13 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$38.37 10-Q · filed 2023-08-21 | -$85.80 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |